blue cross blue shield glp 1 of Mass. sees gains after years of GLP-1-related losses IBX members face GLP-1 drug
Description
Endocr Pract 2018
Some users may notice improvements in appetite control and digestion within weeks, while others may take longer to experience changes
Weight loss and physical activity changes: Patients achieving significant weight loss with GLP-1 therapy may experience changes in exercise tolerance and breathing patterns
Centre for Women's Health and Fertility, India Poli Mara Spritzer, Federal University of Rio Grande Do Sul, Brazil Elisabet Stener-Victorin, Karolinska Institutet, Sweden Fahimeh Ramezani Tehrani, Shahid Beheshti University of Medical Sciences, Iran Shakila Thangaratinam, University of Birmingham, UK Mala Thondan, Harp Family Medical, Australia Eszter Vanky, Norwegian University of Science and Technology
At present, semaglutide holds the maximum share of the GLP-1 market
10.1007/s00125-014-3231-y [DOI] [PubMed] [Google Scholar] 47.Pinto LC, Rados DV, Barkan SS, Leitao CB, Gross JL
